Literature DB >> 27534653

Medical costs incurred by organ damage caused by active disease, comorbidities and side effect of treatments in systemic lupus erythematosus patients: a Taiwan nationwide population-based study.

Y M Chiu1,2, M T Chuang3, H C Lang4.   

Abstract

This study aims to systematically investigate the medial expenditures incurred by systemic lupus erythematosus (SLE)-associated organ damages in order to assess the economic impact of damage accrual by active disease, comorbidities and side effect of treatments. In total, 22,258 SLE cases were identified from the National Health Insurance Research Database, and organ damages assessed were according to the list from Systemic Lupus International Collaborative Clinic/American Rheumatology damage index system. Medical expenditures incurred by organ damages in the first as well as the subsequent year were obtained from the database. Our data reflected that organ damages caused by active disease and comorbidities, such those of renal, neuropsychiatric, pulmonary and cardiovascular systems are among the highest costing of all damage items. This study also shows that significant medical expenditures are incurred by damage items such as those occurring in ocular and musculoskeletal systems, which are typically caused by side effect of treatments such as corticosteroids. The medical expenditure in subsequent year still causes substantial economic burden. This systematic and continuous survey provided important reference of disease burden of SLE.

Entities:  

Keywords:  Medical expenditures; National Health Insurance; Organ damage; Systemic lupus erythematosus

Mesh:

Substances:

Year:  2016        PMID: 27534653     DOI: 10.1007/s00296-016-3551-y

Source DB:  PubMed          Journal:  Rheumatol Int        ISSN: 0172-8172            Impact factor:   2.631


  21 in total

1.  Systemic lupus international collaborative clinics: development of a damage index in systemic lupus erythematosus.

Authors:  D Gladman; E Ginzler; C Goldsmith; P Fortin; M Liang; M Urowitz; P Bacon; S Bombardieri; J Hanly; E Hay
Journal:  J Rheumatol       Date:  1992-11       Impact factor: 4.666

2.  Nationwide population-based epidemiologic study of systemic lupus erythematosus in Taiwan.

Authors:  Y-M Chiu; C-H Lai
Journal:  Lupus       Date:  2010-07-20       Impact factor: 2.911

3.  Economic outcomes in patients diagnosed with systemic lupus erythematosus with versus without nephritis: results from an analysis of data from a US claims database.

Authors:  Elise M Pelletier; Sarika Ogale; Elaine Yu; Paul Brunetta; Jay Garg
Journal:  Clin Ther       Date:  2009-11       Impact factor: 3.393

Review 4.  Cost-of-illness studies in systemic lupus erythematosus: A systematic review.

Authors:  Tracy Y Zhu; Lai Shan Tam; Edmund K Li
Journal:  Arthritis Care Res (Hoboken)       Date:  2011-05       Impact factor: 4.794

5.  Damage in lupus patients--what have we learned so far?

Authors:  L Eder; M B Urowitz; D D Gladman
Journal:  Lupus       Date:  2013-10       Impact factor: 2.911

6.  Medical costs and healthcare resource use in patients with lupus nephritis and neuropsychiatric lupus in an insured population.

Authors:  Daniel E Furst; Ann Clarke; Ancilla W Fernandes; Tim Bancroft; Kavita Gajria; Warren Greth; Serban R Iorga
Journal:  J Med Econ       Date:  2013-02-11       Impact factor: 2.448

Review 7.  The development and initial validation of the Systemic Lupus International Collaborating Clinics/American College of Rheumatology damage index for systemic lupus erythematosus.

Authors:  D Gladman; E Ginzler; C Goldsmith; P Fortin; M Liang; M Urowitz; P Bacon; S Bombardieri; J Hanly; E Hay; D Isenberg; J Jones; K Kalunian; P Maddison; O Nived; M Petri; M Richter; J Sanchez-Guerrero; M Snaith; G Sturfelt; D Symmons; A Zoma
Journal:  Arthritis Rheum       Date:  1996-03

8.  Lymphoma risk in systemic lupus: effects of disease activity versus treatment.

Authors:  Sasha Bernatsky; Rosalind Ramsey-Goldman; Lawrence Joseph; Jean-Francois Boivin; Karen H Costenbader; Murray B Urowitz; Dafna D Gladman; Paul R Fortin; Ola Nived; Michelle A Petri; Soren Jacobsen; Susan Manzi; Ellen M Ginzler; David Isenberg; Anisur Rahman; Caroline Gordon; Guillermo Ruiz-Irastorza; Edward Yelin; Sang-Cheol Bae; Daniel J Wallace; Christine A Peschken; Mary Anne Dooley; Steven M Edworthy; Cynthia Aranow; Diane L Kamen; Juanita Romero-Diaz; Anca Askanase; Torsten Witte; Susan G Barr; Lindsey A Criswell; Gunnar K Sturfelt; Irene Blanco; Candace H Feldman; Lene Dreyer; Neha M Patel; Yvan St Pierre; Ann E Clarke
Journal:  Ann Rheum Dis       Date:  2013-01-08       Impact factor: 19.103

9.  A longitudinal analysis of costs associated with change in disease activity in systemic lupus erythematosus.

Authors:  Hong Kan; Annie Guerin; Michael S Kaminsky; Andrew P Yu; Eric Q Wu; Alfred Denio; Jhingran Priti; Siva Narayanan; Charles Molta
Journal:  J Med Econ       Date:  2013-05-15       Impact factor: 2.448

10.  Characteristics of comorbidities and costs among patients who died from systemic lupus erythematosus in Taiwan.

Authors:  Shih-Chao Kang; Shinn-Jang Hwang; Yu-Sheng Chang; Chung-Tei Chou; Chang-Youh Tsai
Journal:  Arch Med Sci       Date:  2012-09-08       Impact factor: 3.318

View more
  1 in total

1.  An evaluation of costs associated with overall organ damage in patients with systemic lupus erythematosus in the United States.

Authors:  Christopher F Bell; Mayank R Ajmera; Juliana Meyers
Journal:  Lupus       Date:  2022-01-21       Impact factor: 2.911

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.